long intergenic non-protein coding RNA 2308Genealiases: []
Q-omics provides the consensus-scored LINC02308 profile across patient tissues and cancer cell-line models. LINC02308 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02308 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, LINC02308 RNA expression shows 9,123 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, THCA, and BRCA as cancer lineages where LINC02308 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02308 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02308 survival associations across molecular data types. LINC02308 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02308 RNA expression–survival associations across cancer types. High LINC02308 expression shows unfavorable associations in KIRC, UCEC, LGG and CHOL, but favorable associations in SKCM and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02308 RNA expression.
This table summarizes LINC02308 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02308. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02308 shows lower tumor expression in THCA, COAD, KIRC, BLCA, BRCA and STAD. The THCA box plot shows higher LINC02308 RNA expression in normal versus tumor tissue (log2 FC = −1.495, t-test p < 0.001).
This table shows molecular features associated with LINC02308 in patient tissues and cancer cell lines. In patient samples, LINC02308 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
